Laboratory News and Research

RSS

Illumina's board appoints Jacob Thaysen, Ph.D. as its new Chief Executive Officer

llumina today announced that its Board of Directors has appointed Jacob Thaysen, Ph.D., as Chief Executive Officer, effective September 25, 2023.

From Illumina, Inc. 5 Sep 2023

Mutational changes in Avian flu virus could increase risk of transmission to humans

A new study from researchers in China and Nottingham has discovered that a subtype of avian flu virus, endemic in poultry farms in China, is undergoing mutational changes, which could increase the risk of the disease being passed on to humans.

5 Sep 2023

Gut microbes play a starring role in insulin resistance, opening doors for new diabetes treatments

The study reveals a strong association between gut microbial carbohydrate metabolism and insulin resistance, pointing to gut microbes as a key player in metabolic syndrome and type 2 diabetes. Targeting these microbial activities could offer a new therapeutic pathway for improving insulin resistance and overall metabolic health.

4 Sep 2023

The first point-of-care genetic test for lactose intolerance: A compact, lab-on-phone diagnostic assay

The performance of a compact diagnostic assay that can accurately and rapidly diagnose lactose intolerance.

4 Sep 2023

Early life high fructose exposure is associated with increased prevalence of adolescent anxiety disorders

Researchers investigated whether exposure to high fructose in early life directly affects essential microglia function.

4 Sep 2023

New breakthroughs by NPL scientists could transform cancer treatment

New breakthroughs by scientists at the National Physical Laboratory (NPL) are set to transform cancer treatment in the UK and worldwide.

4 Sep 2023

Students starting school and college in September are at increased risk of serious illnesses

A leading testing expert fears a perfect storm of infections in September as students start at schools and colleges. School closures during Covid lockdowns mean 1-in-8 students starting university this year remains unprotected against meningitis. Concern is growing early symptoms may be confused with freshers’ flu.

4 Sep 2023

Oral diabetes drug semaglutide fights obesity in mice: A game-changer for human treatment?

The study reveals that oral semaglutide, a medication primarily used for type 2 diabetes, effectively reduces body weight and blood glucose levels in diet-induced obese mice. The findings suggest that this drug could be a promising treatment for obesity and offer a suitable animal model for future research.

3 Sep 2023

Lessons learned from COVID-19 pandemic can help confront future epidemics

Where did COVID-19 originate? Prof Angus Dalgleish shows that the virus that emerged in Wuhan, China in 2019 had been modified in a laboratory to make it more infectious (for the construction of a more effective vaccine).

1 Sep 2023

Biomarkers unveil insights into post-COVID-19 syndrome variability

Researchers studied a prospective observation cohort of patients with post-coronavirus disease 2019 syndrome.

1 Sep 2023

Unique openings in specific ion channels could lead to development of selective drugs

Ion channels are attractive drug targets due to their importance in health and disease, but finding ways to target a specific ion channel selectively is a major challenge.

31 Aug 2023

Scientists delve deeper into how vaccines work against leishmaniasis

Scientists have established the effectiveness of vaccines they developed to prevent the disfiguring skin disease leishmaniasis in animal studies, and Phase 1 human trial planning is in motion for the most promising candidate.

31 Aug 2023

Socioeconomic distress linked to worse outcomes after heart transplantation

People from socioeconomically distressed communities who underwent heart transplantation between 2004 and 2018 faced a 10% greater relative risk of experiencing graft failure and dying within five years compared to people from non-distressed communities.

31 Aug 2023

Laboratory instrument manufacturer Knauer is now EN ISO 13485 certified

The manufacturer of high-tech laboratory equipment KNAUER Wissenschaftliche Geräte GmbH has passed the certification audit.

From KNAUER Wissenschaftliche Geräte GmbH 31 Aug 2023

Gut microbiome linked to eczema in infancy

A new study has revealed important associations between the gut microbiome and eczema in infancy and has established the basis for the potential prevention and treatment of eczema via modulation of the gut microbiota.

30 Aug 2023

New omicron variants can reinfect people who were infected with earlier variants

The omicron variants of the SARS-CoV-2 virus, which have rapidly spread around the world over the past year, latch onto our cells more tightly, invade them more efficiently, and elude many of the antibodies induced by previous infections and vaccines.

30 Aug 2023

Study finds potential HIV cure using existing cancer drug

An existing blood cancer drug has shown promise in killing 'silent' HIV cells and delaying reinfections – a significant pre-clinical discovery that could lead to a future cure for the disease.

30 Aug 2023

New oral agent shows promise in treatment of relapsed multiple myeloma

A new agent that subverts myeloma cells from within while also subjecting them to an immune system attack produced impressive responses in combination with dexamethasone in patients with multiple myeloma that had relapsed and stopped responding to all currently available therapies, a clinical trial conducted by researchers at Dana-Farber Cancer Institute and around the world has found.

30 Aug 2023

Engineered ACE2 decoy shows promise as COVID-19 treatment

Researchers from Japan demonstrated that an engineered angiotensin-converting enzyme 2 (ACE2) receptor, which showed the potential to remarkably reduce the emergence of resistant virus strains, could successfully exert its therapeutic effect in primates, which may open avenues for the application of the technology for the treatment of humans.

30 Aug 2023

Can muvalaplin achieve safe and tolerable plasma concentrations adequate to reduce steady-state Lp(a) levels without modulating plasminogen activity in humans?

Researchers evaluated the tolerability, safety, pharmacodynamics, and pharmacokinetic properties of muvalaplin.

30 Aug 2023

Previous
1
...
82
83
84
85
86
87
88
...
1826
Next

Laboratory News and Research

Illumina's board appoints Jacob Thaysen, Ph.D. as its new Chief Executive Officer

Mutational changes in Avian flu virus could increase risk of transmission to humans

Gut microbes play a starring role in insulin resistance, opening doors for new diabetes treatments

The first point-of-care genetic test for lactose intolerance: A compact, lab-on-phone diagnostic assay

Early life high fructose exposure is associated with increased prevalence of adolescent anxiety disorders

New breakthroughs by NPL scientists could transform cancer treatment

Students starting school and college in September are at increased risk of serious illnesses

Oral diabetes drug semaglutide fights obesity in mice: A game-changer for human treatment?

Lessons learned from COVID-19 pandemic can help confront future epidemics

Biomarkers unveil insights into post-COVID-19 syndrome variability

Unique openings in specific ion channels could lead to development of selective drugs

Scientists delve deeper into how vaccines work against leishmaniasis

Socioeconomic distress linked to worse outcomes after heart transplantation

Laboratory instrument manufacturer Knauer is now EN ISO 13485 certified

Gut microbiome linked to eczema in infancy

New omicron variants can reinfect people who were infected with earlier variants

Study finds potential HIV cure using existing cancer drug

New oral agent shows promise in treatment of relapsed multiple myeloma

Engineered ACE2 decoy shows promise as COVID-19 treatment

Can muvalaplin achieve safe and tolerable plasma concentrations adequate to reduce steady-state Lp(a) levels without modulating plasminogen activity in humans?

Viva Saliva Book: The ultimate guide to saliva Book preview Download eBook

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest Life Science News